Terms ending in 2029
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,884,110 | Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 8,088,895 | Antibodies That Bind CXCR7 Epitopes In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 8,946,240 | 4-Amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 8,906,938 | C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 9,126,939 | C5AR Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 9,573,897 | C5AR Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,035,768 | C5AR Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,660,897 | C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.